Research reports

Where the field is
heading.

All reports Frontier Deep Dive Regulatory Category Overview 6 reports

Latest report

Frontier R-006 18 min read Five years of peptide patents: what the filings reveal about the next wave of research compounds A five-year map of peptide patent activity, treated as a signal of research investment rather than evidence of efficacy. Read the report

R-005 Deep Dive 12 min read Epitalon and telomeres: separating the signal from the noise in longevity peptide research What the published Epitalon record can support, where methodology limits interpretation and why independent replication matters. R-006 Frontier 18 min read Five years of peptide patents: what the filings reveal about the next wave of research compounds A five-year map of peptide patent activity, treated as a signal of research investment rather than evidence of efficacy. R-001 Category Overview 6 min read Why we built The Compound Index — and what we committed to when we did The editorial rationale behind the Index, our evidence framework and the boundary we maintain between research and commerce. R-003 Regulatory 11 min read UK peptide regulation in 2024: what RUO actually means, and where the legal boundaries sit A dated overview of research-use-only supply in the UK and why labelling alone does not determine legal compliance. R-004 Frontier 16 min read The GLP-1 landscape beyond semaglutide: dual and triple agonists in the research pipeline A mechanism-by-mechanism view of dual and triple agonists, with attention to trial maturity and the limits of cross-compound comparison.

R-002 Deep Dive 14 min read BPC-157 and the evidence gap: what 30 years of pre-clinical data does — and doesn’t — tell us A structured review of the BPC-157 evidence record, from repeated pre-clinical findings to the absence of a robust human clinical evidence base.